文献速递泌尿男性生殖肿瘤

GETUG-AFU 15随机III期试验中转移性去势初治前列腺癌患者接受雄激素剥夺治疗联合或不联合多西他赛的Q-TWiST分析

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
PubMed 文献 · Eur J Cancer · 2017-08-04

基于GETUG-AFU 15 III期试验385例转移性去势初治前列腺癌患者数据,采用Q-TWiST分析评估多西他赛联合ADT与单用ADT在毒性、无进展生存和进展期之间的权衡。当进展状态效用值≤0.2且毒性状态效用值≥0.8时,ADT+多西他赛组质量调整生存更优;进展效用值≥0.4时两组相似。高瘤负荷患者进展效用值<0.35时ADT+多西他赛组Q-TWiST显著获益,低瘤负荷患者任何系数下均无获益。

要点

  • 当进展效用值≤0.2且毒性效用值≥0.8时,ADT+多西他赛组质量调整生存优于单用ADT组。
  • 进展效用值≥0.4时,ADT+多西他赛组与单用ADT组质量调整生存相似。
  • 高瘤负荷患者进展效用值<0.35时ADT+多西他赛组Q-TWiST显著获益,低瘤负荷患者任何系数下均无获益。

核心结论

  • 早期多西他赛可能为转移性去势初治前列腺癌患者提供显著的质量调整生存获益,尤其是高瘤负荷患者,取决于毒性阶段和进展后时间的赋值。
  • Q-TWiST方法学是权衡生存、进展和毒性进行决策的有用工具。

研究设计与样本

  • 基于GETUG-AFU 15 III期随机试验数据的事后分析,纳入385例转移性去势初治前列腺癌患者,比较多西他赛联合雄激素剥夺治疗与单用雄激素剥夺治疗。
  • 将总生存划分为毒性治疗阶段(TOX)、无毒性无进展时间(TWIST)和进展期(PROG)三个健康状态,按患者效用值加权计算质量调整生存时间。
  • 阈值分析中TOX和PROG的效用值在0至1之间变动。

主要发现

  • 当PROG效用值≤0.2且TOX效用值≥0.8时,ADT+多西他赛组质量调整生存优于单用ADT组。
  • 当PROG效用值≥0.4时,ADT+多西他赛组与单用ADT组质量调整生存相似。
  • 按高瘤负荷与低瘤负荷分层,仅高瘤负荷患者在PROG效用值<0.35时ADT+多西他赛组Q-TWiST显著获益。
  • 低瘤负荷患者在所测试的任何系数下均无获益。

关键数值与推荐

  • PROG效用值≤0.2且TOX效用值≥0.8时,ADT+多西他赛组质量调整生存更优。
  • PROG效用值≥0.4时,ADT+多西他赛组与单用ADT组质量调整生存相似。
  • 高瘤负荷患者PROG效用值<0.35时ADT+多西他赛组Q-TWiST显著获益。
  • 低瘤负荷患者在所测试的任何系数下均无Q-TWiST获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early chemotherapy has recently become a new standard of care for patients with metastatic castrate-naive prostate cancer (mCNPC). The survival benefit is evident in patients with high-volume disease, but less clear in those with low-volume disease. Here, we assessed the trade-offs between toxicity and survival using a Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment (Q-TWiST) analysis. PATIENTS AND METHODS: This analysis was performed from the data of the Genito-Urinary Oncology Group (GETUG)-AFU 15 phase III trial evaluating the benefits of docetaxel (D) combined with androgen deprivation therapy (ADT) versus ADT alone in 385 mCNPC patients. Overall survival was partitioned into three periods, namely toxic phase of treatment (TOX), time before progression without toxicity (TWIST), and progression (PROG). These health states were weighted according to patients' utility to determine quality-adjusted survival times. In threshold analyses, utility for TOX and PROG were varied from 0 to 1. RESULTS: A better quality-adjusted survival was found in the ADT + D arm when the utility for PROG and TOX states were ≤0.2 and ≥ 0.8, respectively. When the utility for PROG was 0.4 or more, ADT + D and ADT alone yielded similar quality-adjusted survival. When patients were stratified into high-volume versus low-volume disease, we found a significant Q-TWiST benefit in favour of the ADT + D arm only for high-volume patients when the utility for PROG was less than 0.35, while we found no benefit in low-volume disease patients, whatever the coefficients tested. CONCLUSION: Early docetaxel may provide significant quality-adjusted survival benefits for patients with mCNPC, especially those with high-volume disease, depending on the values assigned to the times spent in the toxicity phase and after PROG. The Q-TWiST methodology is a useful tool for decision-making regarding trade-offs between survival, PROG and toxicity.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Marino P, Sfumato P, Joly F, et al. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Eur J Cancer. 2017. PMID: 28780479. doi:10.1016/j.ejca.2017.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。